A new, rapidly dissolving and thermally stable dry powder Hepatitis-B vaccine

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$939,918.00
Award Year:
2012
Program:
SBIR
Phase:
Phase II
Contract:
2R44AI089149-02
Award Id:
n/a
Agency Tracking Number:
R44AI089149
Solicitation Year:
2012
Solicitation Topic Code:
NIAID
Solicitation Number:
PA11-096
Small Business Information
2100 Central Avenue, BOULDER, CO, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
136952087
Principal Investigator:
STEPHEN CAPE
(303) 350-3060
Stephen.Cape@colorado.edu
Business Contact:
BOB SIEVERS
(303) 350-3060
aktivdry@aol.com
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): The overarching goal of this project is to move a new, dry powder formulation of Hepatitis-B vaccine on its path to commercialization. In the Phase I SBIR we tested in vitro three Hep-B dry powder formulations of commercially available Shanvac-B and demonstrated powder stability and immunogenicity at temperatures ranging from -20 ?C through 65 oC. At these temperature extremes the currently marketed liquid Hepatis B vaccine is inactivated as the HBsAg antigen separates from the alum adjuvant. Our studies also showed that the dry micro-scale powders dissolved very rapidly, suggesting their utility in single dose auto-reconstitution devices aimed at parenteral administration. These results have far-reaching implications inregard to vaccine storage, transport and administration, especially in developing countries where limited refrigeration and electric power and high ambient temperatures restrict the useful life and potency of liquid vaccines. In the proposed Phase II SBIRstudy, we will choose the optimum formulation from the three that we developed earlier and pair this powder with a single dose auto-reconstitution device being developed by Becton Dickinson (BD). The drug- device combination will be used to assess potency in a mouse model compared to a control group of animals that will be administered Shanvac-B by needle and syringe. Potency will be assessed from ELISA analysis of animal sera. . The outcome of the Phase II work will be judged based on the potency of the Hep-B dry powder formulation and the functionality and performance of the BD device as compared with the potency of the needle and syringe administration. PUBLIC HEALTH RELEVANCE: This project seeks to accelerate a new Hepatitis-B vaccineformulation on its path to commercialization. A commercially available thimerosal-free liquid vaccine, Shanvac-B, was formulated as a dry, rapidly dissolving micro-powder with stability over an 18-month period at temperatures ranging from -20 oC through 65oC. When considered in the context of combining Aktiv-Dry's vaccine powders with single dose auto-reconstitution devices, these results have far-reaching implications in regard to vaccine storage, transport and administration, especially in developing countries where limited refrigeration and electric power and high ambient temperatures restrict the useful life and potency of liquid vaccines.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government